Marine Polymer Technologies
Marine Polymer Technologies is a privately held U.S. medical device company founded in 1992, headquartered in Danvers, Massachusetts, focused on the development and delivery of biomaterials with a 51-100 employee team.
- Company typePrivate
- Founded1992
- HeadquartersDanvers, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Marine Polymer Technologies does
Marine Polymer Technologies, Inc. (MPT) is a privately held U.S. medical device company founded in 1992 and headquartered in Danvers, Massachusetts. Per the firmographic record, the company is focused on the development and delivery of biomaterials, operating with a headcount of 51-100 employees. The firm has been in continuous operation for over three decades, suggesting an established, regulated commercial business rather than an early-stage venture.
The company's core competency is biomaterials science applied to medical device applications, though the specific product portfolio, indications (e.g., hemostasis, wound management, surgical adjuncts), underlying polymer chemistry, and regulatory clearances were not accessible from the supplied sources — the corporate website at marinepolymer.com returned only a verification/loading page, and no news or third-party sources were attached. No product list, patent inventory, customer base, distribution network, or pricing model was available to characterize the business model in detail.
The revenue mechanics, go-to-market motion, and customer segmentation are similarly under-documented in the available data. There is no disclosed revenue, funding history, ownership structure, management roster, or pipeline of strategic actions, and no source-attributable claims about partnerships, M&A, geographic footprint, or capital raises. Investors evaluating MPT should treat this as a data-thin profile and source primary diligence directly from FDA registration records, USPTO patent filings, and the company's own materials before drawing conclusions.
Marine Polymer Technologies firmographics
Firmographics- Name
- Marine Polymer Technologies
- Website
- https://marinepolymer.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Marine Polymer Technologies is a privately held U.S. medical device company founded in 1992, headquartered in Danvers, Massachusetts, focused on the development and delivery of biomaterials with a 51-100 employee team.
- Ownership category
- akta.pro rank
Where Marine Polymer Technologies is headquartered
LocationHeadquarters
- HQ city
- Danvers
- HQ country
- United States
- HQ region
- North America
Markets served
Marine Polymer Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Marine Polymer Technologies product offering
Product offeringCore offering
Marine Polymer Technologies, Inc. (MPT) is a medical device company that develops and delivers biomaterial-based products. Its core activity is the research, development, and commercialization of proprietary biomaterials intended for use in medical device applications. The company manufactures and supplies these biomaterial products to the healthcare market.
Differentiator
Problem solved
Functional benefit
Companies that use Marine Polymer Technologies
Customer profileIdeal customer profiles1 record
Marine Polymer Technologies technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Marine Polymer Technologies partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Marine Polymer Technologies competitors and assessment
Company assessmentBroad incumbents
- Johnson & Johnson (Ethicon): Ethicon, J&J's surgical solutions arm, dominates the operating room with hemostats, sealants, and anti-adhesion products. MPT competes and partners in the same surgical adjacencies (anti-adhesion, hemostasis), and Ethicon is the canonical strategic-acquirer comp for any biomaterials medical device target.
- Baxter International: Baxter is a global medical device and biopharmaceutical incumbent with a long-running surgical hemostasis franchise (e.g., Floseal, Tisseel). It overlaps with MPT as an adjacent supplier to the same surgical suites and trauma hospitals, and represents the type of strategic acquirer of a niche biomaterials platform.
- Stryker Corporation: Stryker's surgical and wound-care businesses (acquired with Wright Medical, Instratek) buy into biomaterials and biologic adjacencies. Comparable as a broader MedTech incumbent that the same hospital procurement officers and trauma surgeons might evaluate alongside an MPT proposition.
- Becton, Dickinson and Company (BD): BD operates a broad surgical and biosciences portfolio, including hemostatic and wound-care products sold into the same hospital channels MPT serves. BD is a relevant comparable because it acquires niche biomaterials and hemostatic technology assets to extend its surgical platform.
- Medtronic: Medtronic (post-Covidien) is a leading surgical and biologics franchise with active interest in hemostatic and tissue-adjacent products. Comparable as an OEM-style acquirer of biomaterials platforms with overlapping call points in the OR.
Direct peers
- Teleflex (Z-Medica / QuikClot): Teleflex acquired Z-Medica, which makes kaolin-based QuikClot hemostatic gauze — a direct functional competitor in hemostasis with stronger distribution and military contracts (e.g., CoTCCC guidelines). Comparability centers on competing hemostatic mechanism approaches for the same clinical and tactical indications MPT targets.
- Tricol Biomedical (HemCon): Tricol is the commercial successor to HemCon, the most direct chitosan-based hemostatic gauze competitor to MPT. Both companies monetize marine-derived (chitosan) polymers as FDA-cleared hemostatic devices for surgical and tactical/military use, with overlapping product mechanics and channel to trauma centers and DoD procurement.
Emerging players
- Carmell Therapeutics: Carmell is a clinical-stage company developing allogeneic platelet-derived and biomaterial-based tissue repair products for orthopedics and wound healing. Comparable as a similarly-sized emerging biomaterials platform focused on indications adjacent to MPT's hemostasis and tissue-support franchise.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key highlights5 records
Customer concentration
Marine Polymer Technologies social profiles
Digital presenceMarine Polymer Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Marine Polymer Technologies leadership team
Management profileNumber of profiles
Marine Polymer Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Marine Polymer Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Marine Polymer Technologies
What does Marine Polymer Technologies do?
Marine Polymer Technologies, Inc. (MPT) is a medical device company that develops and delivers biomaterial-based products. Its core activity is the research, development, and commercialization of proprietary biomaterials intended for use in medical device applications. The company manufactures and supplies these biomaterial products to the healthcare market.
Is Marine Polymer Technologies a public or private company?
Marine Polymer Technologies is a private company. It is classified as unknown and is currently operating.
When was Marine Polymer Technologies founded?
Marine Polymer Technologies was founded in 1992. It employs 51 to 100 people.
Where is Marine Polymer Technologies based?
Marine Polymer Technologies is headquartered in Danvers, United States, in the North America region.
Who are Marine Polymer Technologies's main competitors?
Broad incumbents on record are Johnson & Johnson (Ethicon), Baxter International, Stryker Corporation, Becton, Dickinson and Company (BD) and Medtronic. Direct peers are Teleflex (Z-Medica / QuikClot) and Tricol Biomedical (HemCon). Carmell Therapeutics is listed as an emerging player.
Does Marine Polymer Technologies have an API?
No public API is recorded for Marine Polymer Technologies.